P38 MAP kinase plays a role in G2 checkpoint activation and inhibits apoptosis of human B cell lymphoma cells treated with etoposide

Apoptosis

Volumn 10, Issue 5, 2005, Pages 1111-1120

  Kurosu, T ^a   Takahashi, Y ^a   Fukuda, T ^a   Koyama, T ^a   Miki, T ^a   Miura, O ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Etoposide; G2 checkpoint; Lymphoma; p38 MAP kinase

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYCLIN DEPENDENT KINASE 1; ETOPOSIDE; GYRASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MUTANT PROTEIN;

ALPHA CHAIN; AMINO ACID SEQUENCE; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BETA CHAIN; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DAUDI CELL; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; HUMAN CELL; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REGULATORY MECHANISM;

CDC2 PROTEIN KINASE; ETOPOSIDE; G2 PHASE; HUMANS; LYMPHOMA, B-CELL; P38 MITOGEN-ACTIVATED PROTEIN KINASES;

EID: 24644467226     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-005-3372-z     Document Type: Article

References (22)

1. Nyberg KA, Michelson RJ, Putnam CW, Weinert TA. Toward maintaining the genome: DNA damage and replication checkpoints. Annu Rev Genet 2002; 36: 617-656.
2. Sancar A, Lindsey-Boltz LA, Unsal-Kaccmaz K, Linn S. Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints. Annu Rev Biochem 2004; 73: 39-85.
3. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421-429.
4. Zhou BB, Bartek J. Targeting the checkpoint kinases: Chemosensitization versus chemoprotection. Nat Rev Cancer 2004; 4: 216-225.
5. Nebreda AR, Porras A. p38 MAP kinases: Beyond the stress response. Trends Biochem Sci 2000; 25: 257-260.
6. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81: 807-869.
7. Kishi H, Nakagawa K, Matsumoto M, et al. Osmotic shock induces G1 arrest through p53 phosphorylation at Ser33 by activated p38MAPK without phosphorylation at Ser15 and Ser20. J Biol Chem 2001; 276: 39115-39122.
8. Bulavin DV, Saito S, Hollander MC, et al. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. Embo J 1999; 18: 6845-6854.
9. Wang X, McGowan CH, Zhao M, et al. Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest. Mol Cell Biol 2000; 20: 4543-4552.
10. Bulavin DV, Higashimoto Y, Popoff IJ, et al. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature 2001; 411: 102-107.
11. Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS, Pieper RO. The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol Cell Biol 2003; 23: 8306-8315.
12. Jin ZH, Kurosu T, Yamaguchi M, Arai A, Miura O. Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis. Oncogene 2005; in press.
13. Engelman JA, Lisanti MP, Scherer PE. Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesis. J Biol Chem 1998; 273: 32111-32120.
14. Kurosu T, Fukuda T, Miki T, Miura O. BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells. Oncogene 2003; 22: 4459-4468.
15. Sramkoski RM, Wormsley SW, Bolton WE, Crumpler DC, Jacobberger JW. Simultaneous detection of cyclin B1, p105, and DNA content provides complete cell cycle phase fraction analysis of cells that endoreduplicate. Cytometry 1999; 35: 274-283.
16. Mikhailov A, Shinohara M, Rieder CL. Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway. J Cell Biol 2004; 166: 517-526.
17. Lee JC, Kassis S, Kumar S, Badger A, Adams JL. p38 mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials. Pharmacol Ther 1999; 82: 389-397.
18. Bulavin DV, Amundson SA, Fornace AJ. p38 and Chk1 kinases: Different conductors for the G(2)/M checkpoint symphony. Curr Opin Genet Dev 2002; 12: 92-97.
19. Hirose Y, Katayama M, Berger MS, Pieper RO. Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide. J Neurosurg 2004; 100: 1060-1065.
20. Zechner D, Craig R, Hanford DS, McDonough PM, Sabbadini RA, Glembotski CC. MKK6 activates myocardial cell NF-kappaB and inhibits apoptosis in a p38 mitogen-activated protein kinase-dependent manner. J Biol Chem 1998; 273: 8232-8239.
21. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991; 88: 5413-5417.
22. Elenitoba-Johnson KS, Jenson SD, Abbott RT, et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci USA 2003; 100: 7259-7264.